Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 52-Week High – Still a Buy?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)’s share price hit a new 52-week high during trading on Monday . The stock traded as high as $65.30 and last traded at $64.1150, with a volume of 1200 shares changing hands. The stock had previously closed at $64.53.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on KNSA. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Monday, May 4th. Canaccord Genuity Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Jefferies Financial Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Wells Fargo & Company increased their target price on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a report on Wednesday, April 29th. Finally, Zacks Research upgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, Kiniksa Pharmaceuticals International presently has an average rating of “Buy” and a consensus target price of $62.71.

Kiniksa Pharmaceuticals International Trading Down 1.3%

The firm has a fifty day moving average of $54.17 and a two-hundred day moving average of $47.78. The company has a market capitalization of $4.90 billion, a PE ratio of 71.01 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The business had revenue of $214.27 million for the quarter, compared to analysts’ expectations of $206.11 million. During the same period in the previous year, the firm earned $0.11 EPS. The business’s quarterly revenue was up 55.5% on a year-over-year basis. On average, equities analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.25 EPS for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, insider John F. Paolini sold 58,424 shares of Kiniksa Pharmaceuticals International stock in a transaction on Friday, May 1st. The shares were sold at an average price of $53.71, for a total value of $3,137,953.04. Following the transaction, the insider directly owned 65,623 shares of the company’s stock, valued at $3,524,611.33. The trade was a 47.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Michael R. Megna sold 6,625 shares of the company’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $46.69, for a total transaction of $309,321.25. Following the sale, the chief accounting officer owned 27,418 shares of the company’s stock, valued at $1,280,146.42. This represents a 19.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 636,755 shares of company stock valued at $33,222,062. 51.98% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of large investors have recently made changes to their positions in the business. Qube Research & Technologies Ltd increased its stake in shares of Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after buying an additional 653,236 shares during the period. Rubric Capital Management LP lifted its stake in Kiniksa Pharmaceuticals International by 15.6% in the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after acquiring an additional 526,567 shares during the period. Bank of America Corp DE lifted its stake in Kiniksa Pharmaceuticals International by 220.9% in the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock worth $35,436,000 after acquiring an additional 506,576 shares during the period. Cubist Systematic Strategies LLC boosted its holdings in Kiniksa Pharmaceuticals International by 213.2% in the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock valued at $18,192,000 after acquiring an additional 447,536 shares in the last quarter. Finally, Spruce Street Capital LP purchased a new position in Kiniksa Pharmaceuticals International during the 4th quarter valued at $17,943,000. 53.95% of the stock is currently owned by institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.